tiprankstipranks
Nurix Therapeutics, Inc. (NRIX)
NASDAQ:NRIX
US Market
Want to see NRIX full AI Analyst Report?

Nurix Therapeutics (NRIX) Stock Forecast & Price Target

594 Followers
See the Price Targets and Ratings of:

NRIX Analyst Ratings

Strong Buy
13Ratings
Strong Buy
12 Buy
1 Hold
0 Sell
Based on 13 analysts giving stock ratings to
Nurix
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

NRIX Stock 12 Month Forecast

Average Price Target

$34.17
▲(95.13% Upside)
Based on 13 Wall Street analysts offering 12 month price targets for Nurix Therapeutics in the last 3 months. The average price target is $34.17 with a high forecast of $45.00 and a low forecast of $25.00. The average price target represents a 95.13% change from the last price of $17.51.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"8":"$8","27":"$27","46":"$46","17.5":"$17.5","36.5":"$36.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":45,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$45.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":34.166666666666664,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$34.17</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$25.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[8,17.5,27,36.5,46],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,23.91,25.532307692307693,27.154615384615383,28.776923076923076,30.39923076923077,32.02153846153846,33.643846153846155,35.26615384615384,36.88846153846154,38.51076923076923,40.13307692307693,41.755384615384614,43.37769230769231,{"y":45,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,23.91,24.698974358974358,25.48794871794872,26.276923076923076,27.065897435897433,27.854871794871794,28.64384615384615,29.432820512820513,30.22179487179487,31.010769230769228,31.79974358974359,32.58871794871794,33.37769230769231,{"y":34.166666666666664,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,23.91,23.993846153846153,24.077692307692306,24.161538461538463,24.245384615384616,24.32923076923077,24.413076923076922,24.49692307692308,24.58076923076923,24.664615384615384,24.748461538461537,24.832307692307694,24.916153846153847,{"y":25,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":11.71,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.04,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.11,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.4,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.94,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.91,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.97,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.09,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.81,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.48,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.81,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.39,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.91,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$45.00Average Price Target$34.17Lowest Price Target$25.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Wells Fargo Analyst forecast on NRIX
Wells Fargo
Wells Fargo
$25
Hold
42.78%
Upside
Reiterated
07/14/26
Analysts Offer Insights on Healthcare Companies: Voyager Therapeutics (NASDAQ: VYGR), Axsome Therapeutics (NASDAQ: AXSM) and Nurix Therapeutics (NASDAQ: NRIX)
Mizuho Securities Analyst forecast on NRIX
Mizuho Securities
Mizuho Securities
$30$34
Buy
94.17%
Upside
Reiterated
07/13/26
Nurix Therapeutics price target raised to $34 from $30 at MizuhoNurix Therapeutics price target raised to $34 from $30 at Mizuho
H.C. Wainwright Analyst forecast on NRIX
H.C. Wainwright
H.C. Wainwright
$32$34
Buy
94.17%
Upside
Reiterated
07/10/26
Nurix Therapeutics price target raised to $34 from $32 at H.C. WainwrightNurix Therapeutics price target raised to $34 from $32 at H.C. Wainwright
Truist Financial Analyst forecast on NRIX
Truist Financial
Truist Financial
$32$34
Buy
94.17%
Upside
Reiterated
07/10/26
Analysts Offer Insights on Healthcare Companies: Nurix Therapeutics (NASDAQ: NRIX) and Insulet (NASDAQ: PODD)
Needham Analyst forecast on NRIX
Needham
Needham
$34
Buy
94.17%
Upside
Reiterated
07/10/26
Analysts Are Bullish on Top Healthcare Stocks: Nurix Therapeutics (NRIX), Johnson & Johnson (JNJ)
Stifel Nicolaus Analyst forecast on NRIX
Stifel Nicolaus
Stifel Nicolaus
$40
Buy
128.44%
Upside
Assigned
07/10/26
Nurix Therapeutics (NRIX) Receives a Buy from Stifel Nicolaus
Oppenheimer Analyst forecast on NRIX
Oppenheimer
Oppenheimer
$28
Buy
59.91%
Upside
Reiterated
07/10/26
Oppenheimer Sticks to Its Buy Rating for Nurix Therapeutics (NRIX)
RBC Capital Analyst forecast on NRIX
RBC Capital
RBC Capital
$30$33
Buy
88.46%
Upside
Assigned
07/09/26
Analysts Offer Insights on Healthcare Companies: TruBridge (NASDAQ: TBRG), AbbVie (NYSE: ABBV) and Nurix Therapeutics (NASDAQ: NRIX)
Jefferies Analyst forecast on NRIX
Jefferies
Jefferies
$45
Buy
157.00%
Upside
Reiterated
07/08/26
Analysts Conflicted on These Healthcare Names: Certara (NASDAQ: CERT), Nurix Therapeutics (NASDAQ: NRIX) and Vertex Pharmaceuticals (NASDAQ: VRTX)
BTIG
$30$32
Buy
82.75%
Upside
Assigned
07/01/26
Analysts Offer Insights on Healthcare Companies: Nurix Therapeutics (NASDAQ: NRIX), Taysha Gene Therapies (NASDAQ: TSHA) and Zymeworks (NASDAQ: ZYME)
J.P. Morgan Analyst forecast on NRIX
J.P. Morgan
J.P. Morgan
Buy
Reiterated
06/11/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Morgan Stanley Analyst forecast on NRIX
Morgan Stanley
Morgan Stanley
$15$36
Buy
105.60%
Upside
Reiterated
06/08/26
Morgan Stanley’s Terence Flynn Reiterates Buy on Nurix, Citing Value-Creating Roche Partnership and Long‑Term Bexobrutideg Growth Potential
Piper Sandler Analyst forecast on NRIX
Piper Sandler
Piper Sandler
$35
Buy
99.89%
Upside
Reiterated
05/13/26
Piper Sandler Sticks to Their Buy Rating for Nurix Therapeutics (NRIX)
UBS
$26$23
Buy
31.35%
Upside
Reiterated
11/10/25
Analysts Offer Insights on Healthcare Companies: Catalyst Pharma (NASDAQ: CPRX), Rapid Micro Biosystems (NASDAQ: RPID) and Nurix Therapeutics (NASDAQ: NRIX)
Barclays Analyst forecast on NRIX
Barclays
Barclays
$31
Buy
77.04%
Upside
Reiterated
10/23/25
Barclays Remains a Buy on Nurix Therapeutics (NRIX)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Wells Fargo Analyst forecast on NRIX
Wells Fargo
Wells Fargo
$25
Hold
42.78%
Upside
Reiterated
07/14/26
Analysts Offer Insights on Healthcare Companies: Voyager Therapeutics (NASDAQ: VYGR), Axsome Therapeutics (NASDAQ: AXSM) and Nurix Therapeutics (NASDAQ: NRIX)
Mizuho Securities Analyst forecast on NRIX
Mizuho Securities
Mizuho Securities
$30$34
Buy
94.17%
Upside
Reiterated
07/13/26
Nurix Therapeutics price target raised to $34 from $30 at MizuhoNurix Therapeutics price target raised to $34 from $30 at Mizuho
H.C. Wainwright Analyst forecast on NRIX
H.C. Wainwright
H.C. Wainwright
$32$34
Buy
94.17%
Upside
Reiterated
07/10/26
Nurix Therapeutics price target raised to $34 from $32 at H.C. WainwrightNurix Therapeutics price target raised to $34 from $32 at H.C. Wainwright
Truist Financial Analyst forecast on NRIX
Truist Financial
Truist Financial
$32$34
Buy
94.17%
Upside
Reiterated
07/10/26
Analysts Offer Insights on Healthcare Companies: Nurix Therapeutics (NASDAQ: NRIX) and Insulet (NASDAQ: PODD)
Needham Analyst forecast on NRIX
Needham
Needham
$34
Buy
94.17%
Upside
Reiterated
07/10/26
Analysts Are Bullish on Top Healthcare Stocks: Nurix Therapeutics (NRIX), Johnson & Johnson (JNJ)
Stifel Nicolaus Analyst forecast on NRIX
Stifel Nicolaus
Stifel Nicolaus
$40
Buy
128.44%
Upside
Assigned
07/10/26
Nurix Therapeutics (NRIX) Receives a Buy from Stifel Nicolaus
Oppenheimer Analyst forecast on NRIX
Oppenheimer
Oppenheimer
$28
Buy
59.91%
Upside
Reiterated
07/10/26
Oppenheimer Sticks to Its Buy Rating for Nurix Therapeutics (NRIX)
RBC Capital Analyst forecast on NRIX
RBC Capital
RBC Capital
$30$33
Buy
88.46%
Upside
Assigned
07/09/26
Analysts Offer Insights on Healthcare Companies: TruBridge (NASDAQ: TBRG), AbbVie (NYSE: ABBV) and Nurix Therapeutics (NASDAQ: NRIX)
Jefferies Analyst forecast on NRIX
Jefferies
Jefferies
$45
Buy
157.00%
Upside
Reiterated
07/08/26
Analysts Conflicted on These Healthcare Names: Certara (NASDAQ: CERT), Nurix Therapeutics (NASDAQ: NRIX) and Vertex Pharmaceuticals (NASDAQ: VRTX)
BTIG
$30$32
Buy
82.75%
Upside
Assigned
07/01/26
Analysts Offer Insights on Healthcare Companies: Nurix Therapeutics (NASDAQ: NRIX), Taysha Gene Therapies (NASDAQ: TSHA) and Zymeworks (NASDAQ: ZYME)
J.P. Morgan Analyst forecast on NRIX
J.P. Morgan
J.P. Morgan
Buy
Reiterated
06/11/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Morgan Stanley Analyst forecast on NRIX
Morgan Stanley
Morgan Stanley
$15$36
Buy
105.60%
Upside
Reiterated
06/08/26
Morgan Stanley’s Terence Flynn Reiterates Buy on Nurix, Citing Value-Creating Roche Partnership and Long‑Term Bexobrutideg Growth Potential
Piper Sandler Analyst forecast on NRIX
Piper Sandler
Piper Sandler
$35
Buy
99.89%
Upside
Reiterated
05/13/26
Piper Sandler Sticks to Their Buy Rating for Nurix Therapeutics (NRIX)
UBS
$26$23
Buy
31.35%
Upside
Reiterated
11/10/25
Analysts Offer Insights on Healthcare Companies: Catalyst Pharma (NASDAQ: CPRX), Rapid Micro Biosystems (NASDAQ: RPID) and Nurix Therapeutics (NASDAQ: NRIX)
Barclays Analyst forecast on NRIX
Barclays
Barclays
$31
Buy
77.04%
Upside
Reiterated
10/23/25
Barclays Remains a Buy on Nurix Therapeutics (NRIX)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
ENOVEnovis
GKOSGlaukos
IMUXImmunic
AVTXAvalo Therapeutics
TARAProtara Therapeutics
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Nurix Therapeutics

3 Months
Peter LawsonBarclays
Success Rate
9/16 ratings generated profit
56%
Average Return
+10.69%
Copying Peter Lawson's trades and holding each position for 3 Months would result in 56.25% of your transactions generating a profit, with an average return of +10.69% per trade.
1 Year
Robert BurnsH.C. Wainwright
Success Rate
12/17 ratings generated profit
71%
Average Return
+58.31%
Copying Robert Burns's trades and holding each position for 1 Year would result in 70.59% of your transactions generating a profit, with an average return of +58.31% per trade.
2 Years
Peter LawsonBarclays
Success Rate
15/16 ratings generated profit
94%
Average Return
+53.96%
Copying Peter Lawson's trades and holding each position for 2 Years would result in 93.75% of your transactions generating a profit, with an average return of +53.96% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

NRIX Analyst Recommendation Trends

Rating
Mar 26
Apr 26
May 26
Jun 26
Jul 26
Strong Buy
14
13
17
25
15
Buy
3
0
1
4
11
Hold
0
0
0
1
2
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
17
13
18
30
28
In the current month, NRIX has received 26 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. NRIX average Analyst price target in the past 3 months is 34.17.
Each month's total comprises the sum of three months' worth of ratings.

NRIX Financial Forecast

NRIX Earnings Forecast

The previous quarter’s earnings for NRIX were -$0.81.
The previous quarter’s earnings for NRIX were -$0.81.

NRIX Sales Forecast

The previous quarter’s earnings for NRIX were $9.04M.
The previous quarter’s earnings for NRIX were $9.04M.

NRIX Stock Forecast FAQ

What is NRIX’s average 12-month price target, according to analysts?
Based on analyst ratings, Nurix Therapeutics, Inc.’s 12-month average price target is 34.17.
    What is NRIX’s upside potential, based on the analysts’ average price target?
    Nurix Therapeutics, Inc. has 95.13% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is NRIX a Buy, Sell or Hold?
          Nurix Therapeutics, Inc. has a consensus rating of Strong Buy which is based on 12 buy ratings, 1 hold ratings and 0 sell ratings.
            What is Nurix Therapeutics, Inc.’s price target?
            The average price target for Nurix Therapeutics, Inc. is 34.17. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $45.00 ,the lowest forecast is $25.00. The average price target represents 95.13% Increase from the current price of $17.51.
              What do analysts say about Nurix Therapeutics, Inc.?
              Nurix Therapeutics, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 13 Wall Streets Analysts.
                How can I buy shares of NRIX?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.